Citius Oncology, Inc. (CTOR)
Automate Your Wheel Strategy on CTOR
With Tiblio's Option Bot, you can configure your own wheel strategy including CTOR - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol CTOR
- Rev/Share 0.0
- Book/Share 0.4528
- PB 3.7987
- Debt/Equity 0.1173
- CurrentRatio 0.3455
- ROIC -0.6821
- MktCap 143643117.0
- FreeCF/Share 0.0
- PFCF 1136839.7822
- PE -4.6306
- Debt/Assets 0.0414
- DivYield 0
- ROE -0.6838
- Rating D+
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | CTOR | Maxim Group | Hold | Buy | -- | $6 | Sept. 23, 2025 |
News
Citius Oncology Deploys AI Platform to Amplify the Performance of its Commercial Team Ahead of LYMPHIR Launch
Published: August 22, 2025 by: PRNewsWire
Sentiment: Neutral
Proprietary model informs targeted sales and marketing strategies with feedback loop that augments precision and impact of targeting and engagement CRANFORD, N.J. , Aug. 22, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), a late-stage biopharmaceutical company developing and commercializing first-in-class critical care products, today announced that it has deployed an innovative AI platform to support its commercial team with advanced data analytics and insights ahead of the anticipated launch of LYMPHIR™, a novel therapy for cutaneous T-cell lymphoma (CTCL).
Read More
Citius Oncology Announces Pricing of $9.0 Million Public Offering
Published: July 16, 2025 by: PRNewsWire
Sentiment: Neutral
CRANFORD, N.J. , July 16, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), a majority-owned subsidiary of Citius Pharmaceuticals, Inc. (Nasdaq: CTXR), today announced the pricing of its "reasonable best-efforts" public offering of 6,818,182 shares of common stock of the Company and warrants to purchase shares of common stock at a public offering price of $1.32 per share.
Read More
Citius Oncology, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update
Published: February 14, 2025 by: PRNewsWire
Sentiment: Neutral
CRANFORD, N.J. , Feb. 14, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), a specialty biopharmaceutical company focused on the development and commercialization of novel targeted oncology therapies, today reported business and financial results for the fiscal first quarter ended December 31, 2024.
Read More
Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update
Published: February 14, 2025 by: PRNewsWire
Sentiment: Neutral
CRANFORD, N.J. , Feb. 14, 2025 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today reported business and financial results for the fiscal first quarter ended December 31, 2024.
Read More
About Citius Oncology, Inc. (CTOR)
- IPO Date
- Website None
- Industry Drug Manufacturers - General
- CEO Leonard L. Mazur
- Employees None